INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 160 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,172,375 | -64.0% | 37,077 | +52.6% | 0.15% | -36.8% |
Q3 2021 | $3,260,000 | -60.7% | 24,300 | -52.5% | 0.23% | -57.3% |
Q2 2021 | $8,290,000 | +91.5% | 51,200 | -5.1% | 0.55% | +76.2% |
Q1 2021 | $4,329,000 | -12.0% | 53,937 | -40.3% | 0.31% | -6.3% |
Q4 2020 | $4,918,000 | +196.3% | 90,400 | +8.3% | 0.33% | +201.8% |
Q3 2020 | $1,660,000 | -22.7% | 83,509 | -18.2% | 0.11% | -24.7% |
Q2 2020 | $2,147,000 | +70.3% | 102,143 | -0.9% | 0.15% | +46.0% |
Q1 2020 | $1,261,000 | +0.5% | 103,100 | +20.6% | 0.10% | +29.9% |
Q4 2019 | $1,255,000 | +61.5% | 85,517 | +46.9% | 0.08% | +67.4% |
Q3 2019 | $777,000 | -18.6% | 58,200 | -0.2% | 0.05% | -17.9% |
Q2 2019 | $954,000 | -20.4% | 58,288 | -33.6% | 0.06% | -16.4% |
Q4 2018 | $1,198,000 | -52.3% | 87,743 | +0.0% | 0.07% | -35.6% |
Q3 2018 | $2,511,000 | -13.8% | 87,726 | -17.6% | 0.10% | -6.3% |
Q2 2018 | $2,914,000 | +19.9% | 106,509 | -7.6% | 0.11% | +35.4% |
Q1 2018 | $2,431,000 | – | 115,254 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |